LncRNA ROR和TGF-β1在乳腺癌患者中的表达及临床意义

Abstract
Figure/Table
References (31)
Related Citation (15)

Download: PDF (870 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the expression and clinical significance of long noncoding RNA ROR (LncRNA ROR) and transforming growth factor-β1 (TGF-β1) in breast cancer patients. Methods A total of 73 patients with breast cancer who were first diagnosed by pathology in Dongguan People’s Hospital of Guangdong Province (hereinafter referred to as “our hospital”) from January 2018 to June 2019 were selected as group A, 37 patients with benign breast lesions treated in our hospital during the same period were selected as group B and 37 healthy subjects who underwent physical examination were selected as group C. Serum LncRNA ROR levels were detected by real time fluorescence quantitative reverse transcription polymerase chain reaction (qRT-PCR), serum TGF-β1 levels were detected by enzyme-linked immunoadsordent assay, and serum carbohydrate antigen 153 (CA153) and carcinoembryonic antigen (CEA) levels were detected by electrochemiluminescence. The expression differences of LncRNA ROR, TGF-β1, CA153, and CEA of subjects in the three groups were observed, and the clinical value of LncRNA ROR, TGF-β1, CA153, and CEA in the diagnosis of breast cancer. The effects of age, degree of differentiation, clinical stage, lymph node metastasis, and phenotype on the expression of LncRNA ROR, TGF-β1, CA153, and CEA were observed. Results LncRNA ROR and TGF-β1 in group A were higher than those in group B and group C, the differences were statistically significant (P ＜ 0.05). Spearman correlation analysis showed that LncRNA ROR was positively correlated with TGF-β1 (r = 0.897, P < 0.05). The levels of CA153 and CEA in group A were higher than those in group B and group C, and the differences were statistically significant (P ＜ 0.05). The levels of CA153 and CEA in group B were higher than those in group C, and the differences were statistically significant (P ＜ 0.05). There was no significant difference between LncRNA ROR and TGF-β1 in predicting area under the curve (AUC) of breast cancer (P ＞ 0.05). LncRNA ROR and TGF-β1 predicted higher AUC than CA153 and CEA, the differences were statistically significant (P ＜ 0.05). There were statistically significant differences in LncRNA ROR and TGF-β1 levels among breast cancer patients with different clinical tumor stages (P ＜ 0.05). Serum LncRNA ROR and TGF-β1 levels in breast cancer patients with lymph node metastasis were higher than those in patients without lymph node metastasis, the differences were statistically significant (P ＜ 0.05). Conclusion Serum LncRNA ROR and TGF-β1 may be potential markers for breast cancer diagnosis. The expression of serum LncRNA ROR and TGF-β1 is correlated with tumor stage and lymph node metastasis, which has certain reference value for prognosis.

Key words： Breast Cancer Long noncoding RNA Transforming growth factor-β1 Prognosis

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHANG Yujuan YE Huirong YUAN Huiling WANG Yongxia

Cite this article:

ZHANG Yujuan YE Huirong YUAN Huiling WANG Yongxia. Expression and clinical significance of LncRNA ROR and TGF-β1 in patients with breast cancer#br#[J]. 中国医药导报, 2022, 19(5): 105-109,123.

URL:

https://www.yiyaodaobao.com.cn/EN/ OR https://www.yiyaodaobao.com.cn/EN/Y2022/V19/I5/105

[1] 姚颖，陆奎英，张敏，等.miRNA-10b与乳腺癌相关肿瘤标志物在早期乳腺癌中诊断效能比较[J].国际检验医学杂志，2020，41（3）：310-313，317.
[2] 陈馨，张薇，张伟杰，等.肿瘤相关巨噬细胞CD163在乳腺癌组织中的表达及对乳腺癌细胞生物学特性的影响[J].疑难病杂志，2020，19（3）：292-297.
[3] 王琳，沈佳丽，熊世双，等.JAG1和Notch3在乳腺癌组织中的表达及预后价值[J].临床肿瘤学杂志，2020，25（1）：13-19.
[4] 刘丹娜，吴通，陈露，等.个体化基因检测指导下的晚期三阴性乳腺癌化疗优势人群的选择模型建立[J].实用临床医药杂志，2021，25（8）：11-15.
[5] 禚映辰，张培国，张李婷，等.NLRCs基因在乳腺癌中的表达和预后判断中的价值[J].肿瘤预防与治疗，2021，34（3）：221-227.
[6] 李晓敏，查文娟，铁小伟，等.LncRNA SBF2-AS1在恶性肿瘤中的作用及其机制[J].现代肿瘤医学，2021，29（18）：3290-3294.
[7] 何瑾瑜，于姣.LncRNA MIR100HG靶向miR-142-5p诱导肝癌细胞对索拉菲尼的耐药机制研究[J].河北医药，2021，43（9）：1291-1295.
[8] 曹鸣菲，雷德财，宋晓玉，等.长链非编码RNA-ROR在乳腺癌诊断中的潜在应用研究[J].国际检验医学杂志，2019，40（17）：2077-2080，2084.
[9] 栗浩然，王雅莉，李红娟，等.lncRNA FAL1通过调控MAPK通路对卵巢癌细胞化疗耐药性的影响及其机制[J].肿瘤防治研究，2021，48（4）：333-340.
[10] 胡世丰，雷春，施炜，等.LncRNA-ROR抑制结直肠癌细胞转移的作用研究[J].蚌埠医学院学报，2020，45（5）：569-571，577.
[11] 张立冬，李辉，李娟.LncRNA ROR和LncRNA ATB在膀胱癌患者中的表达情况及其临床意义[J].检验医学与临床，2018，15（14）：2103-2107.
[12] 邵林，李同相，肖睿，等.沉默LncRNA TUG1对骨肉瘤细胞放射敏感性影响[J].中国矫形外科杂志，2021，29（14）：1313-1318.
[13] 陈乙香，洪金妮，陈捷.长链非编码RNA在卵巢癌的调控机制及中西医治疗研究进展[J].中医药临床杂志，2021， 33（7）：1390-1394.
[14] 蒋欣成，何贵金，刘飞，等.LncRNA AL022344.7促进乳腺癌细胞增殖，侵袭和上皮-间质转化[J].解剖科学进展，2021，27（4）：409-412.
[15] 张勇.长链非编码RNA ROR1-AS1促进骨肉瘤细胞侵袭的机制研究[J].中国医药导报，2020，17（22）：25-28，197.
[16] 刘帅臣，李玉明.长链非编码RNA Linc-ROR与恶性肿瘤发生、发展关系的研究进展[J].医学研究杂志，2019， 48（7）：16-19.
[17] 单晓英，张祥华，王岩.冬凌草甲素通过调控LncRNA-H19抑制急性髓系白血病细胞增殖和促细胞凋亡研究[J].中国医药科学，2020，10（19）：33-37，47.
[18] 杨永.长链非编码RNA Linc00152、H19、ROR在食管癌患者中的表达及临床意义[J].国际检验医学杂志，2019， 40（2）：226-229，233.
[19] 曹征，谢连娣，范宗静，等.黄芪多糖联合lncRNA TUG1沉默对缺血再灌注人心脏微血管内皮细胞凋亡的影响[J].世界中医药，2021，16（21）：3185-3190.
[20] 赵喜博，刘巍，冯书君，等.长链非编码RNA ROR在恶性肿瘤中的作用及相关机制[J].国际免疫学杂志，2018， 41（4）：467-471.
[21] 单晓英，张祥华，王岩.探讨沉默LncRNA-H19联合小剂量冬凌草甲素对APL细胞增殖和凋亡的影响[J].西部中医药，2021，34（8）：35-39.
[22] Bai F，Zhang LH，Liu X，et al. GATA3 functions downstream of BRCA1 to suppress EMT in breast cancer [J]. Theranostics，2021，11（17）：8218-8233.
[23] Zhao T，Wu L，Li X，et al. Large intergenic non-coding RNA-ROR as a potential biomarker for the diagnosis and dynamic monitoring of breast cancer [J]. Cancer Biomark，2017，20（2）：165-173.
[24] 王文廉，万里新，屈中玉，等.XIAP、TGF-β1和vimentin在乳腺癌中的表达及临床意义[J].癌症进展，2019，17（9）：1057-1060.
[25] 吴悠，殷开宇，李远，等.丙泊酚下调TGF-β1抑制乳腺癌细胞迁移和侵袭能力[J].第三军医大学学报，2018， 40（24）：2236-2242.
[26] Hou L，Tu J，Cheng F，et al. Long noncoding RNA ROR promotes breast cancer by regulating the TGF-βpathway [J]. Cancer Cell Int，2018，18：142.
[27] 李国政.HER2阳性乳腺癌治疗的研究进展[J].实用肿瘤学杂志，2020，34（1）：74-78.
[28] 孙阳，安改丽，段兰英，等.HER2嵌合抗原受体T细胞治疗乳腺癌的进展与展望[J].中国临床研究，2021，34（8）：1113-1116.
[29] Moradian C，Rahbarizadeh F. PE38-based gene therapy of HER2-positive breast cancer stem cells via VHH-redirected polyamidoamine dendrimers [J]. Sci Rep，2021， 11（1）：15517.
[30] Merry CR，McMahon S，Thompson CL，et al. Integrative transcriptome-wide analyses reveal critical HER2-regulated mRNAs and lincRNAs in HER2+breast cancer [J]. Breast Cancer Res Treat，2015，150（2）：321-334.
[31] Luo C，Cao J，Peng R，et al. Functional Variants in Linc-ROR are Associated with mRNA Expression of Linc-ROR and Breast Cancer Susceptibility [J]. Sci Rep，2018， 8（1）：4680.